Atrial Fibrillation, Stroke
Conditions
Keywords
shared decision making, oral anticoagulant, atrial fibrillation, stroke, decision to treat
Brief summary
Randomized study concerning the effect of the number of risk diagrams (with treatment +/- without treatment), the period of stroke risk estimation (one year or five years) and the target of prescription (the patient with atrial fibrillation or the physician himself, imagining she/he has atrial fibrillation) on the intention to prescribe or not oral anticoagulation.
Detailed description
Objectives: To answer the questions: 1. Concerning the decision to prescribe (take) treatment on the basis of a decision aid, are there necessary both diagrams (that with risk without treatment, and that with risk under treatment), or it is enough only the second (risk under treatment, which normally gives all the needed information)? 2. Concerning the decision to prescribe (take) treatment, is it a difference between the effects of the presentation on decision aid of the risk of stroke for the next 1 year, and the presentation of the estimated risk of stroke for the next 5 years? 3. Is the decision different if physicians prescribe the anticoagulant treatment to patients, over if they should take it themselves? Study: 2x3 factorial randomized controlled trial (RCT) for comparison: 1. Between the decision aid with 2 images (without treatment + with treatment) and the one with 1 image (risk only with treatment) 2. Between the effect of the presentation of the stroke risk chart for 1 year and the stroke risk chart for 5 years. 3. The decision to prescribe to patients over the decision to take the treatment themselves. The comparison will be made for the spectrum of risks (scores CHA2DS2-VASC) from 1-5. Sample size: was calculated a sample of 948 participants (474 + 474) for p = 0.05, power = 80% statistical difference between decisions of 5% (from 95% to 90%). The study does not have enough power neither to compare the 5 groups CHA2DS2-VASC (but we will make these comparisons with exploratory purpose), nor to test interactions. Participants: physicians participating to the National Congress of Internal Medicine, physicians participating to courses, professional manifestations. Randomization: randomization will be done on graph type (1 or 2 pictures), duration of risk estimate (1 year and 5 years) and the size of CHA2DS2-VASC risk score (1 to 5), and target prescription (patient or the doctor himself), a total of 40 possibilities. Randomization will be done in blocks of 40. Participants will be asked to decide, depending on the risk chart, if the patient (or himself) will be treated, ignoring the risk of bleeding. The chart will contain the pictogram according to the CHA2DS2-VASC risk score, without communicating the actual score, and the physician will have to make the decision to treat or not, depending on the perceived risk, and not on treatment guidelines. No. questionnaire: first digit = number of risk diagrams (1 or 2); second digit = number of years for which the risk of stroke is calculated (1 or 5); third digit = CHA2DS2-VASC score (1-5). Ex: 253: 2 decision aid diagrams (with and without treatment), with an estimated risk of stroke for the next five years, in a patient with CHA2DS2-VASC score =3. Effect (outcome): decision to treat / not to treat the patient / physician himself, with oral anticoagulants. Statistical analysis: It will look for differences in bivariate analysis, and multivariate = logistic regression (dependent variable = treatment decision, the independent variables = number of charts, period for risk assessment (one or 5 years), prescription target (patient or the physician himself), CHA2DS2-VASC score, time from graduation, medical/teaching grade, working in hospital / ambulatory, the size of the city the physician works in, specialty, gender, age, if the physician has/had someone close with stroke (data from questionnaires).
Interventions
decision aid with one/two diagrams decision aid with risk over one/five years decision aid with CHA2DS2-VASC risk score 1 to 5 target of the prescription: patient / physician hinself
Sponsors
Study design
Eligibility
Inclusion criteria
* physicians who prescribe anticoagulant treatment for atrial fibrillation (cardiology, internal medicine, family medicine, hematology) or who deal with patients with stroke (neurology, pathology) or bleeding (gastroenterology)
Exclusion criteria
* physicians who never prescribe anticoagulant treatments, or do not deal with patients with stroke or bleeding because of anticoagulants
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants Who Prescribed Oral Anticoagulants (OAC) According to the Number of Decision Aid Diagrams | after seeing the decision aid (5 min) | after regarding the risk diagram, the physician will decide to prescribe/take or not the treatment |
Other
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants Who Prescribed Oral Anticoagulants (OAC) According to the Timeframe for Risk Presentation (1 vs 5 Years) | 5 minutes | the proportion of physicians deciding to prescribe OAC after seeing risk estimation on 1 vs 5 years |
| Number of Participants Who Prescribed Oral Anticoagulants (OAC) According to the Target of Prescription (Patient vs. Physician Himself) | 5 min | the participant physicians were randomized to prescribe to virtual patients or to imagine that the risk seen in the diagram was that of themselves |
| Number of Participants Who Prescribed Oral Anticoagulants (OAC) According to the CHA2D2s-VASC Risk Score | 5 min | The proportion of OAC prescription for the range 1-5 of CHA2D2s-VASC scores. CHA2D2S-VASC risk score ranges from 1-5, with higher scores indicating a greater risk of stroke. |
Countries
Romania
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| All Participants all participants in the study (968) | 968 |
| Total | 968 |
Baseline characteristics
| Characteristic | All Participants |
|---|---|
| Age, Continuous | 39 years |
| Region of Enrollment Romania | 968 participants |
| Sex: Female, Male Female | 704 Participants |
| Sex: Female, Male Male | 264 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | — / — | — / — |
| other Total, other adverse events | 0 / 486 | 0 / 482 |
| serious Total, serious adverse events | 0 / 486 | 0 / 482 |
Outcome results
Number of Participants Who Prescribed Oral Anticoagulants (OAC) According to the Number of Decision Aid Diagrams
after regarding the risk diagram, the physician will decide to prescribe/take or not the treatment
Time frame: after seeing the decision aid (5 min)
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| One Diagram | Number of Participants Who Prescribed Oral Anticoagulants (OAC) According to the Number of Decision Aid Diagrams | 400 participants |
| Two Diagrams | Number of Participants Who Prescribed Oral Anticoagulants (OAC) According to the Number of Decision Aid Diagrams | 406 participants |
Number of Participants Who Prescribed Oral Anticoagulants (OAC) According to the CHA2D2s-VASC Risk Score
The proportion of OAC prescription for the range 1-5 of CHA2D2s-VASC scores. CHA2D2S-VASC risk score ranges from 1-5, with higher scores indicating a greater risk of stroke.
Time frame: 5 min
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| One Diagram | Number of Participants Who Prescribed Oral Anticoagulants (OAC) According to the CHA2D2s-VASC Risk Score | 146 participants |
| Two Diagrams | Number of Participants Who Prescribed Oral Anticoagulants (OAC) According to the CHA2D2s-VASC Risk Score | 159 participants |
| CHA2D2S-VASC Risk Score 3 | Number of Participants Who Prescribed Oral Anticoagulants (OAC) According to the CHA2D2s-VASC Risk Score | 164 participants |
| CHA2D2S-VASC Risk Score 4 | Number of Participants Who Prescribed Oral Anticoagulants (OAC) According to the CHA2D2s-VASC Risk Score | 172 participants |
| CHA2D2S-VASC Risk Score 5 | Number of Participants Who Prescribed Oral Anticoagulants (OAC) According to the CHA2D2s-VASC Risk Score | 165 participants |
Number of Participants Who Prescribed Oral Anticoagulants (OAC) According to the Target of Prescription (Patient vs. Physician Himself)
the participant physicians were randomized to prescribe to virtual patients or to imagine that the risk seen in the diagram was that of themselves
Time frame: 5 min
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| One Diagram | Number of Participants Who Prescribed Oral Anticoagulants (OAC) According to the Target of Prescription (Patient vs. Physician Himself) | 442 participants |
| Two Diagrams | Number of Participants Who Prescribed Oral Anticoagulants (OAC) According to the Target of Prescription (Patient vs. Physician Himself) | 364 participants |
Number of Participants Who Prescribed Oral Anticoagulants (OAC) According to the Timeframe for Risk Presentation (1 vs 5 Years)
the proportion of physicians deciding to prescribe OAC after seeing risk estimation on 1 vs 5 years
Time frame: 5 minutes
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| One Diagram | Number of Participants Who Prescribed Oral Anticoagulants (OAC) According to the Timeframe for Risk Presentation (1 vs 5 Years) | 412 participants |
| Two Diagrams | Number of Participants Who Prescribed Oral Anticoagulants (OAC) According to the Timeframe for Risk Presentation (1 vs 5 Years) | 394 participants |